Equillium, Inc. (EQ) stock
EQNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.32−0.10 (-7.04%)
Close on Nov 12, 2026Market cap $83.70MP/E –Yield –
Equillium ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Equillium's ebitda for the twelve months ending Sep 30, 2023 was -$9.16M. For fiscal 2022 it was -$61.96M. The highest annual figure on record is -$8.61M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$61.96M | – |
| FY2021 | Dec 31, 2021 | -$37.71M | – |
| FY2020 | Dec 31, 2020 | -$29.50M | – |
| FY2019 | Dec 31, 2019 | -$26.70M | – |
| FY2018 | Dec 31, 2018 | -$8.61M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | -$3.59M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.08M | – |
| Q4 FY2022 | Dec 31, 2022 | $2.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.21M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.52M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.30M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.37M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.84M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.95M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.60M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.44M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.61M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.43M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.34M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.23M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.22M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.12M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.04M | – |
See a number that looks wrong?